Navigation Links
Migenix averts proxy contest; reaches agreement with DJohnson holdings
Date:8/11/2008

ences British Columbia (formerly BCBiotech).

Andrew Rae - Mr. Rae is the chief executive officer and president of iCo Therapeutics Inc., an ocular development company he co-founded in 2005. Mr. Rae has spent a decade in the biotechnology industry, formerly as chief financial officer with Ability Biomedical Corporation. Mr. Rae has also served as vice president, Finance and Corporate Affairs at Active Pass Pharmaceuticals. Previously, Mr. Rae served as biotechnology equities analyst at Goepel Shields & Partners (now Raymond James Ltd.), covering Canadian biotechnology stocks.

To facilitate a resolution between the parties, Dr. James DeMesa has also agreed to resign as president and chief executive officer of MIGENIX effective immediately. Bruce Schmidt has been appointed as interim president and chief executive officer of MIGENIX.

Dr. Jim DeMesa, resigning president and chief executive officer of MIGENIX, commented: "We are pleased a solution between MIGENIX and DJohnson has been reached. As a result of a detailed assessment of MIGENIX's current financial condition, the opportunities which lie ahead, and the standby commitment for a rights offering that has been made by DJohnson, the board determined that a settlement with DJohnson was in the best interests of shareholders."

Doug Johnson, president of DJohnson, stated, "I am glad the impending proxy battle has been resolved. I am pleased to have myself, Bruce Schmidt and Andrew Rae join the board of directors to help guide MIGENIX in realizing its objectives. Our agreement with MIGENIX increases shareholder representation on our board and is consistent with our commitment of accountability to shareholders."

As a first step, the new board will concentrate its efforts on raising additional capital to finance MIGENIX's pipeline projects and for general working capital purposes. Doug Johnson commented, "We are committed to raising funds for MIGENIX in a manner that is fair to all shareh
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Notice of MIGENIX General Meeting of Shareholders
2. MIGENIX Fourth Quarter and Fiscal Year 2008 Financial Results Conference Call & Webcast Notification
3. MIGENIX Corporate Update and Requisition of Special Meeting
4. Migenix Takes Operational Actions To Extend Cash Past Upcoming Key Milestones
5. MIGENIX Appoints Pieter Dorsman to Board of Directors
6. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
7. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
8. MIGENIX releases CEO message #22
9. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
10. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
11. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Bill Jacobs Automotive, a group of car dealerships headquartered ... the Heartland Blood Center and offering free oil change coupons ... place Saturday, Jan. 18 at the Bill Jacobs Cadillac and ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  The Bill Jacobs ...
(Date:1/15/2014)... 2014 Cynvenio, a cancer diagnostics company ... genomic analysis of tumor cells in the bloodstream, today ... cancer decision support application powered by CollabRx, Inc. ... genomic test, Therapy Finder will provide breast cancer patients ...
(Date:1/15/2014)... , January 15, 2014 A study has ... on the Formula 1 track could help to tackle the ... Technologies (MAT), Stowhealth (a GP surgery based in Stowmarket) and ... provider Simplyhealth. Telemetry technology, which is inspired by ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 DTS Language ... its Online Web Portal for Life Science organizations who need ... specify the subject matter of their documents in advance with ... help reduce time-to-delivery of translations, often a critical factor in ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2
... International,Corporation (Nasdaq: PRXL ) announced today it ... Conference in New York, NY. James,Winschel, Senior Vice ... formal presentation on PAREXEL at 1:20 p.m. EST ... be available under the "Upcoming Events" section,on PAREXEL,s ...
... Inc. (Nasdaq: SVNT ) today announced the submission ... (FDA) seeking approval to,market pegloticase in the United States ... includes data from both the six-month,placebo controlled Phase 3 ... Extension (OLE) study. The data set includes 101 patients ...
... MEETING, Pa., Oct. 31 /Xinhua-PRNewswire-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: BJGP; ... present at the following conferences:, 1. ... in New York. Management is currently scheduled ... on Monday, November 3. A webcast of this presentation will ...
Cached Biology Technology:PAREXEL International to Present at Oppenheimer 19th Annual Healthcare Conference 2Savient Submits Biologics License Application (BLA) for pegloticase 2Savient Submits Biologics License Application (BLA) for pegloticase 3Savient Submits Biologics License Application (BLA) for pegloticase 4BMP Sunstone Announces Participation in November Investor Conferences 2
(Date:7/9/2014)... 2014) Emerging fungal pathogens pose a greater ... causing population declines of amphibians, bats, corals, bees ... South Florida published in the prestigious journal ... or immunological resistance to a deadly chytrid fungus ... "Acquired resistance is important because it is the ...
(Date:7/9/2014)... Researchers from The Cancer Genome Atlas (TCGA) Research ... cancer-causing pathway in lung adenocarcinoma, the most common ... changes may expand the number of possible therapeutic ... greater number of patients with treatable mutations because ... already exist. , TCGA is jointly funded and ...
(Date:7/9/2014)... may be able to cope with the rising salinity of ... Arctic today is best known for its tundra and polar ... to 38 million years ago during what is known as ... huge temperate forest with brackish water, home to a variety ... and giant tortoises. Much of what is known about the ...
Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... known already for its role in schizophrenia ... according to a report in todays advance on-line issue ... Deaconess Medical Center (BIDMC), the study further suggests that ... diagnostic marker and therapeutic supplement for the treatment of ...
... which glows under ultraviolet light have shown that up ... cleaned. Their findings, published in BioMed Centrals journal, BMC ... bacteria Clostridium difficile (C. difficile) linger in the loo ... Michelle Alfa and a team of scientists from Manitoba, ...
... technology, DALLAS, May 7 An innovator ... will provide its proven public key,infrastructure to the ... on machine readable travel documents (MRTDs),-- also known ... nearly 23 million,citizens by the end of 2008., ...
Cached Biology News:A new gene trigger for pregnancy disorder identified 2UV lotion lights the way to cleaner facilities 2Entrust, Hewlett Packard Partner to Deploy Taiwanese ePassports, Authenticate Biometric Data 2Entrust, Hewlett Packard Partner to Deploy Taiwanese ePassports, Authenticate Biometric Data 3
... Perhaps sheer in-house demand is causing shortages in ... antibody. This can cause unwanted distractions, problems and ... for your hard work and endeavour! Bring us ... and market it internationally. We work under ISO ...
... Neuromedin U-23 (rat) - Diluted Antiserum for ... Neuromedin U-23 (rat) Immunology Products, Host: ... For our corresponding peptide and ... please see Neuromedin U-23 (rat) (H-9295) and ...
... Topoisomerase I from vaccinia virus is ... both positive and negative superhelical turns (also ... closed DNA. The product of the reaction ... fewer positive or negative superhelical turns. DNA ...
...
Biology Products: